Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials

Open access

Abstract

BackgroundGastroprotectant drugs are used for the prevention and treatment of peptic ulcer disease and might reduce its associated complications, but reliable estimates of the effects of gastroprotectants in different clinical settings are scarce. We aimed to examine the effects of proton-pump inhibitors (PPIs), prostaglandin analogues, and histamine-2 receptor antagonists (H2RAs) in different clinical circumstances by doing meta-analyses of tabular data from all relevant unconfounded randomised trials of gastroprotectant drugs.MethodsWe searched MEDLINE and Embase from Jan 1, 1950, to Dec 31, 2015, to identify unconfounded, randomised trials of a gastroprotectant drug (defined as a PPI, prostaglandin analogue, or H2RA) versus control, or versus another gastroprotectant. Two independent researchers reviewed the search results and extracted the prespecified outcomes and key characteristics for each trial. We did meta-analyses of the effects of gastroprotectant drugs on ulcer development, bleeding, and mortality overall, according to the class of gastroprotectant, and according to the individual drug within a gastroprotectant class.FindingsWe identified comparisons of gastroprotectant versus control in 849 trials (142 485 participants): 580 prevention trials (110 626 participants), 233 healing trials (24 033 participants), and 36 trials for the treatment of acute upper gastrointestinal bleeding (7826 participants). Comparisons of one gastroprotectant drug versus another were available in 345 trials (64 905 participants), comprising 160 prevention trials (32 959 participants), 167 healing trials (28 306 participants), and 18 trials for treatment of acute upper gastrointestinal bleeding (3640 participants). The median number of patients in each trial was 78 (IQR 44·0–210·5) and the median duration was 1·4 months (0·9–2·8). In prevention trials, gastroprotectant drugs reduced development of endoscopic ulcers (odds ratio [OR] 0·27, 95% CI 0·25–0·29; p<0·0001), symptomatic ulcers (0·25, 0·22–0·29; p<0·0001), and upper gastrointestinal bleeding (0·40, 0·32–0·50; p<0·0001), but did not significantly reduce mortality (0·85, 0·69–1·04; p=0·11). Larger proportional reductions in upper gastrointestinal bleeding were observed for PPIs than for other gastroprotectant drugs (PPIs 0·21, 99% CI 0·12–0·36; prostaglandin analogues 0·63, 0·35–1·12; H2RAs 0·49, 0·30–0·80; phet=0·0005). Gastroprotectant drugs were effective in preventing bleeding irrespective of the use of non-steroidal anti-inflammatory drugs (phet=0·56). In healing trials, gastroprotectants increased endoscopic ulcer healing (3·49, 95% CI 3·28–3·72; p<0·0001), with PPIs more effective (5·22, 99% CI 4·00–6·80) than prostaglandin analogues (2·27, 1·91–2·70) and H2RAs (3·80, 3·44–4·20; phet<0·0001). In trials among patients with acute bleeding, gastroprotectants reduced further bleeding (OR 0·68, 95% CI 0·60–0·78; p<0·0001), blood transfusion (0·75, 0·65–0·88; p=0·0003), further endoscopic intervention (0·56, 0·45–0·70; p<0·0001), and surgery (0·72, 0·61–0·84; p<0·0001), but did not significantly reduce mortality (OR 0·90, 0·72–1·11; p=0·31). PPIs had larger protective effects than did H2RAs for further bleeding (phet=0·0107) and blood transfusion (phet=0·0130).InterpretationGastroprotectants, in particular PPIs, reduce the risk of peptic ulcer disease and its complications and promote healing of peptic ulcers in a wide range of clinical circumstances. However, this meta-analysis might have overestimated the benefits owing to small study bias.FundingUK Medical Research Council and the British Heart Foundation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2468-1253(18)30037-2

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 PRISMA diagram *Full-text copies of these articles were unobtainable from all available sources including the British Library. †Some trials were published in more than one article (and, conversely, a few articles reported results from more than one trial).
Figure 1 PRISMA diagram *Full-text copies of these articles were unobtainable from all available sources including the British Library. †Some trials were published in more than one article (and, conversely, a few articles reported results from more than one trial).CC BY · PubMed Central
Figure 2 Prevention trials: effects of gastroprotectants on endoscopic and symptomatic ulcers For 97 trials for the endoscopic outcome and 36 trials for the symptomatic outcome, in which the total number of ulcers was not reported but the breakdown was, we assumed that the total number of ulcers was equal to gastric plus duodenal: 1256 of 7414 events vs 2277 of 5766 events for endoscopic ulcers and 469 of 2492 events vs 927 of 2021 events for symptomatic ulcers. PPI=proton-pump inhibitor. H2RA=histamine-2 receptor antagonist. *Summary odds ratios, indicated by diamonds, are presented with 95% CIs; all other odds ratios are presented with 99% CIs.
Figure 2 Prevention trials: effects of gastroprotectants on endoscopic and symptomatic ulcers For 97 trials for the endoscopic outcome and 36 trials for the symptomatic outcome, in which the total number of ulcers was not reported but the breakdown was, we assumed that the total number of ulcers was equal to gastric plus duodenal: 1256 of 7414 events vs 2277 of 5766 events for endoscopic ulcers and 469 of 2492 events vs 927 of 2021 events for symptomatic ulcers. PPI=proton-pump inhibitor. H2RA=histamine-2 receptor antagonist. *Summary odds ratios, indicated by diamonds, are presented with 95% CIs; all other odds ratios are presented with 99% CIs.CC BY · PubMed Central
Figure 3 Prevention trials: effects of gastroprotectants on ulcer complications and all-cause mortality PPI=proton-pump inhibitor. H2RA=histamine-2 receptor antagonist. *Summary odds ratios, indicated by diamonds, are presented with 95% CIs; all other odds ratios are presented with 99% CIs.
Figure 3 Prevention trials: effects of gastroprotectants on ulcer complications and all-cause mortality PPI=proton-pump inhibitor. H2RA=histamine-2 receptor antagonist. *Summary odds ratios, indicated by diamonds, are presented with 95% CIs; all other odds ratios are presented with 99% CIs.CC BY · PubMed Central
Figure 4 Prevention trials: effects of gastroprotectants on endoscopic and symptomatic ulcers, bleeds, and all-cause mortality, subdivided by use of NSAIDs We categorised trials by NSAID use, defining NSAID use as at least 80% of patients took a traditional NSAID, coxib, or aspirin, and no NSAID use as fewer than 80% of patients took a traditional NSAID, coxib, or aspirin. NSAID=non-steroidal anti-inflammatory drugs. *Summary odds ratios, indicated by diamonds, are presented with 95% CIs; all other odds ratios are presented with 99% CIs.
Figure 4 Prevention trials: effects of gastroprotectants on endoscopic and symptomatic ulcers, bleeds, and all-cause mortality, subdivided by use of NSAIDs We categorised trials by NSAID use, defining NSAID use as at least 80% of patients took a traditional NSAID, coxib, or aspirin, and no NSAID use as fewer than 80% of patients took a traditional NSAID, coxib, or aspirin. NSAID=non-steroidal anti-inflammatory drugs. *Summary odds ratios, indicated by diamonds, are presented with 95% CIs; all other odds ratios are presented with 99% CIs.CC BY · PubMed Central
Figure 5 Healing trials: effects of gastroprotectants on ulcer healing We counted the number of patients who became ulcer free on endoscopy post treatment. For 204 trials for the endoscopic outcome, the total number of ulcers was not reported but the breakdown was; we assumed that the total number of ulcers was equal to gastric plus duodenal: 8861 of 11 844 events vs 4040 of 8312 events. PPI=proton-pump inhibitor. H2RA=histamine-2 receptor antagonist. *Summary odds ratios, indicated by diamonds, are presented with 95% CIs; all other odds ratios are presented with 99% CIs.
Figure 5 Healing trials: effects of gastroprotectants on ulcer healing We counted the number of patients who became ulcer free on endoscopy post treatment. For 204 trials for the endoscopic outcome, the total number of ulcers was not reported but the breakdown was; we assumed that the total number of ulcers was equal to gastric plus duodenal: 8861 of 11 844 events vs 4040 of 8312 events. PPI=proton-pump inhibitor. H2RA=histamine-2 receptor antagonist. *Summary odds ratios, indicated by diamonds, are presented with 95% CIs; all other odds ratios are presented with 99% CIs.CC BY · PubMed Central
Figure 6 Acute upper gastrointestinal bleeding treatment trials: effects of gastroprotectants on further bleeding, need for blood transfusion, endoscopic interventions, surgery, and all-cause mortality PPI=proton-pump inhibitor. H2RA=histamine-2 receptor antagonist. *Summary odds ratios, indicated by diamonds, are presented with 95% CIs; all other odds ratios are presented with 99% CIs.
Figure 6 Acute upper gastrointestinal bleeding treatment trials: effects of gastroprotectants on further bleeding, need for blood transfusion, endoscopic interventions, surgery, and all-cause mortality PPI=proton-pump inhibitor. H2RA=histamine-2 receptor antagonist. *Summary odds ratios, indicated by diamonds, are presented with 95% CIs; all other odds ratios are presented with 99% CIs.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 287

Metadata

Authors
Scally, B., Emberson, J. R., Spata, E., Reith, C., Davies, K., Halls, H., Holland, L., Wilson, K., Bhala, N., Hawkey, C., Hochberg, M., Hunt, R., Laine, L., Lanas, A., Patrono, C., & Baigent, C.
Affiliations
  • Glasgow Royal Infirmary (GB)
  • MRC Population Health Research Unit (GB)
  • University of Oxford (GB)
  • Queen Elizabeth Hospital Birmingham (GB)
  • Queen's Medical Centre (GB)
  • University of Maryland, Baltimore (US)
  • McMaster University (CA)
  • Yale University (US)
  • Università Cattolica del Sacro Cuore (IT)
Corresponding author
Baigent, Colin
Venue
The Lancet Gastroenterology & Hepatology
Publisher
Elsevier BV
Published
2018-04
Volume
3
Issue
4
Pages
231-241
ISSN
  • 2468-1156 (ISSN-L)
  • 2468-1253
OpenAlex
W2788189477
Cited by
259
References
27
Citations by year
2026: 25 · 2025: 37 · 2024: 35 · 2023: 30 · 2022: 34 · 2021: 25 · 2020: 38 · 2019: 23 · 2018: 12
FWCI
5.45
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet. Gastroenterology & hepatology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Zaguan (Universidad de Zaragoza) (submittedVersion, cc-by)
Funders
  • British Heart Foundation
  • Medical Research Council
Topics
  • Health Sciences › Medicine › Gastroenterology › Helicobacter pylori-related gastroenterology studies
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal Bleeding Diagnosis and Treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
Keywords
peptic ulcer, proton pump inhibitors, prostaglandin analogues, H2 receptor antagonists, ulcer prevention, ulcer healing, upper gastrointestinal bleeding, peptic ulcer mortality, drug comparison, adverse effects, drug safety, bleeding complications, drug interactions with anticoagulants, drug
MeSH terms
Anti-Inflammatory Agents, Non-Steroidal, Anti-Ulcer Agents, Histamine H2 Antagonists, Humans, Peptic Ulcer, Peptic Ulcer Hemorrhage, Prostaglandins, Synthetic, Proton Pump Inhibitors, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. https://app.cochat.ai/papers/10.1016/s2468-1253(18)30037-2
The paper
Scally, B., Emberson, J. R., Spata, E., Reith, C., Davies, K., Halls, H., Holland, L., Wilson, K., Bhala, N., Hawkey, C., Hochberg, M., Hunt, R., Laine, L., Lanas, A., Patrono, C., & Baigent, C. (2018). Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. The Lancet Gastroenterology & Hepatology. https://doi.org/10.1016/s2468-1253(18)30037-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.